Keo Tabane

740 citations
2 papers · 593 · 1 hit paper · h-index 2

Impact in

    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics
  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • Cancer Treatment and Pharmacology

Papers in

    • Bone health and treatments 1
    • Cancer Immunotherapy and Biomarkers 1
    • Breast Cancer Treatment Studies 1

Keo Tabane

2 papers receiving 584 citations

Keo Tabane's Hit Papers

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 2021 · 589 citations
5890+1+3Years since publication100200300400500

Peers

Keo Tabane
Comparison fields: 5 of 33
  • Cancer Research 264
  • Oncology 347
  • Biomaterials 21
  • Pulmonary and Respiratory Medicine 45
  • Immunology 19
Replace K. Kaneko with:
K. Kaneko Japan
Sipahee Lal Patel India
Adrián Nervo Argentina
Rüdiger Liersch Germany
Fabien Brocard France
R. Pedersini Italy
Noa Ben Baruch Israel
Y. Yanagita Japan
Tamar Peretz Switzerland
Paula Podolski Croatia
Keo Tabane relative to K. Kaneko Japan K. Kaneko's profile →
Citations per field
00.5×1.5×
K. Kaneko · 1×
Citations per year

Countries citing papers authored by Keo Tabane

Since Specialization
Citations

This map shows the geographic impact of Keo Tabane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keo Tabane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keo Tabane more than expected).

Fields of papers citing papers by Keo Tabane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keo Tabane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keo Tabane. The network helps show where Keo Tabane may publish in the future.

Co-authors

The 1 scholars most cited alongside Keo Tabane, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Keo Tabane Line = papers co-authored together Keo Tabane links everyone, so they are left out of the graph.

All Works

2 of 2 papers shown
#Work
1
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
Hit paper breakdown →
2021589
2 20114

About Keo Tabane

Keo Tabane is a scholar working on Oncology, Cancer Research, Nuclear Energy and Engineering, Waste Management and Disposal and Infectious Diseases, having authored 2 papers that have together received 593 indexed citations. Recurring topics across this work include Bone health and treatments (1 paper), Breast Cancer Treatment Studies (1 paper) and Cancer Immunotherapy and Biomarkers (1 paper). The work is most often cited by research in Cancer Research (264 citations), Oncology (347 citations), Biomaterials (21 citations), Pulmonary and Respiratory Medicine (45 citations) and Immunology (19 citations). Keo Tabane has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Daniel Vorobiof. Their work appears in journals such as Current Treatment Options in Oncology and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact